Skip to search formSkip to main contentSkip to account menu

Bispecific Human Anti-ANG-2/Anti-VEGF-A Antibody RO5520985

Known as: Ang2-VEGF-A CrossMab RO5520985, RG7221, RO5520985 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.
5549 Background: Vanucizumab is a bi-specific human IgG1 antibody, simultaneously blocking the complementary roles of Ang-2 and… 
2013
2013
Abstract B86: Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic…
Purpose: VEGF-A blockade has been validated clinically as a treatment for human cancers. Angiopoietin-2 (Ang-2) expression has… 
2013
2013
Cancer Therapy : Preclinical Ang-2-VEGF-A CrossMab , a Novel Bispeci fi c Human IgG 1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously , Mediates Potent Antitumor , Antiangiogenic , and…
Purpose:VEGF-A blockade has been clinically validated as a treatment for human cancers. Angiopoietin2 (Ang-2) expression has been… 
2012
2012
Abstract 2319: Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMAb shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side…
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL VEGF-A blockade has been extensively clinically… 
2011
2011
Abstract 3285: Ang-2-VEGF CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 function mediates potent anti-tumoral and anti-angiogenic efficacy
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL VEGF-A blockade has been validated clinically as a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)